検索対象:     
報告書番号:
※ 半角英数字
 年 ~ 
 年

PET imaging of norepinephrine transporter-expressing tumors using $$^{76}$$Br-${it meta}$-bromobenzylguanidine

$$^{76}$$Br-${it meta}$-bromobenzylguanidineを用いたノルエピネフリントランスポーター発現腫瘍のPETイメージング

渡邉 茂樹; 花岡 宏史*; Liang, J. X.; 飯田 靖彦*; 遠藤 啓吾*; 石岡 典子

Watanabe, Shigeki; Hanaoka, Hirofumi*; Liang, J. X.; Iida, Yasuhiko*; Endo, Keigo*; Ishioka, Noriko

${it Meta}$-iodobenzylguanidine (MIBG) labeled has been widely used for the diagnosis and radiotherapy of norepinephrine transporter (NET)-expressing tumors. This study demonstrated that a positron emitter $$^{76}$$Br labeled ${it meta}$-bromobenzylguanidine ($$^{76}$$Br-MBBG) was prepared and evaluated as a potential PET tracer for imaging NET-expressing tumors. $$^{76}$$Br-MBBG was stable in vitro, but some time-dependent dehalogenation was observed after administration in normal mice. MBBG showed high uptake in PC-12 tumor cells, and this uptake was significantly decreased by the addition of NET inhibitors. In biodistribution, MBBG showed high tumor accumulation (32.0 $$pm$$ 18.6% ID/g at 3 h p.i.) and the tumor-to-blood ratio reached as high as 54.4 $$pm$$ 31.9. Tumor uptake of MBBG correlated very well with that of $$^{125}$$I-MIBG (r = 0.997), but not with $$^{18}$$F-FDG. MBBG-PET showed a very clear image of the transplanted tumor with high sensitivity, and the visualized lesion was different from that by FDG-PET. These results indicated that $$^{76}$$Br-MBBG would be a potential PET tracer for imaging NET-expressing neuroendocrine tumors, and could provide useful information for determining the indications for $$^{131}$$I-MIBG therapy.

Access

:

- Accesses

InCites™

:

パーセンタイル:54.22

分野:Radiology, Nuclear Medicine & Medical Imaging

Altmetrics

:

[CLARIVATE ANALYTICS], [WEB OF SCIENCE], [HIGHLY CITED PAPER & CUP LOGO] and [HOT PAPER & FIRE LOGO] are trademarks of Clarivate Analytics, and/or its affiliated company or companies, and used herein by permission and/or license.